279 related articles for article (PubMed ID: 17414883)
1. The role of FDG PET in the management of lymphoma: what is the evidence base?
Kirby AM; Mikhaeel NG
Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?
Weber WA
J Nucl Med; 2007 Oct; 48(10):1580-2. PubMed ID: 17909256
[No Abstract] [Full Text] [Related]
3. The role of FDG PET in the management of lymphoma: practical guidelines.
Kirby AM; George Mikhaeel N
Nucl Med Commun; 2007 May; 28(5):355-7. PubMed ID: 17414884
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of therapy for lymphoma.
Jerusalem G; Hustinx R; Beguin Y; Fillet G
Semin Nucl Med; 2005 Jul; 35(3):186-96. PubMed ID: 16098292
[TBL] [Abstract][Full Text] [Related]
5. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
6. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
Kostakoglu L; Gallamini A
J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
[TBL] [Abstract][Full Text] [Related]
7. PET: too much of a good thing? Does the plethora of choices impact on patient management?
Divgi C; Pandit-Taskar N
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):398. PubMed ID: 15761778
[No Abstract] [Full Text] [Related]
8. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
10. PET imaging for response assessment in lymphoma: potential and limitations.
Schöder H; Moskowitz C
Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
[TBL] [Abstract][Full Text] [Related]
11. PET evaluation of lung cancer.
Bunyaviroch T; Coleman RE
J Nucl Med; 2006 Mar; 47(3):451-69. PubMed ID: 16513615
[No Abstract] [Full Text] [Related]
12. When should FDG-PET be used in the modern management of lymphoma?
Barrington SF; Mikhaeel NG
Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies.
Basu S; Alavi A
Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):427-8. PubMed ID: 17195072
[No Abstract] [Full Text] [Related]
14. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
15. Impact of fluorodeoxyglucose PET on the management of esophageal cancer.
Salavati A; Basu S; Heidari P; Alavi A
Nucl Med Commun; 2009 Feb; 30(2):95-116. PubMed ID: 19194210
[TBL] [Abstract][Full Text] [Related]
16. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
17. 18F-DOPA PET/CT and neuroendocrine tumours.
Nanni C; Rubello D; Fanti S
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):509-13. PubMed ID: 16912994
[No Abstract] [Full Text] [Related]
18. Utility of 18F-FDG PET in evaluating cancers of lung.
Acker MR; Burrell SC
J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET in monitoring therapy of breast cancer.
Biersack HJ; Bender H; Palmedo H
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S112-7. PubMed ID: 15112111
[TBL] [Abstract][Full Text] [Related]
20. Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management.
Chan SC; Yen TC; Ng SH; Lin CY; Wang HM; Liao CT; Fan KH; Chang JT
J Nucl Med; 2006 Sep; 47(9):1447-54. PubMed ID: 16954552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
